Skip to main content
Erschienen in: Journal of Neurology 1/2015

01.01.2015 | Original Communication

A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation

verfasst von: Rita Barone, M. Carrozzi, R. Parini, R. Battini, D. Martinelli, M. Elia, M. Spada, F. Lilliu, G. Ciana, A. Burlina, V. Leuzzi, M. Leoni, L. Sturiale, G. Matthijs, J. Jaeken, M. Di Rocco, D. Garozzo, A. Fiumara

Erschienen in: Journal of Neurology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

PMM2-CDG (PMM2 gene mutations) is the most common congenital disorder of N-glycosylation. We conducted a nationwide survey to characterize the frequency, clinical features, glycosylation and genetic correlates in Italian patients with PMM2-CDG. Clinical information was obtained through a questionnaire filled in by the referral physicians including demographics, neurological and systemic features, neuroimaging data and genotype. Glycosylation analyses of serum transferrin were complemented by MALDI-Mass Spectrometry (MALDI-MS). Between 1996 and 2012, data on 37 Italian patients with PMM2-CDG were collected. All the patients with a severe phenotype were unable to walk unaided, 84 % had severe intellectual disability and 81 % microcephaly. Conversely, among 17 mildly affected patients 82 % had independent ambulation, 64 % had borderline to mild intellectual disability and 35 % microcephaly. Epilepsy and stroke-like events did not occur among patients with the mild phenotype. The rate and extent of systemic involvement were more pronounced in severely affected patients. The L32R misfolding mutation of the PMM2 gene occurred in 70 % of the patients with the mild phenotype and was associated with a less severe underglycosylation of serum Tf at MALDI-MS analyses. Despite their different disease severity, all patients had progressive (olivo)ponto-cerebellar atrophy that was the hallmark clinical feature for the diagnosis. A mild neurological phenotype of PMM2-CDG marked by preserved ambulatory ability and autonomy and associated with L32R mutation is particularly frequent in Italy. PMM2-CDG should be considered in patients with even mild developmental disability and/or unexplained progressive cerebellar atrophy.
Literatur
1.
Zurück zum Zitat Freeze HH, Chong JX, Bamshad MJ, Ng BG (2014) Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet 94:161–175PubMedCentralCrossRefPubMed Freeze HH, Chong JX, Bamshad MJ, Ng BG (2014) Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet 94:161–175PubMedCentralCrossRefPubMed
2.
Zurück zum Zitat Marquardt T, Denecke J (2003) Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr 162:359–379PubMed Marquardt T, Denecke J (2003) Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies. Eur J Pediatr 162:359–379PubMed
3.
Zurück zum Zitat Funke S, Gardeitchik T, Kouwenberg D et al (2013) Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A 161A:578–584CrossRefPubMed Funke S, Gardeitchik T, Kouwenberg D et al (2013) Perinatal and early infantile symptoms in congenital disorders of glycosylation. Am J Med Genet A 161A:578–584CrossRefPubMed
5.
Zurück zum Zitat Barone R, Sturiale L, Garozzo D (2009) Mass spectrometry in the characterization of human genetic N-Glycosylation defects. Mass Spectrom Rev 28:517–542CrossRefPubMed Barone R, Sturiale L, Garozzo D (2009) Mass spectrometry in the characterization of human genetic N-Glycosylation defects. Mass Spectrom Rev 28:517–542CrossRefPubMed
7.
Zurück zum Zitat Grünewald S (2009) The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta 1792:827–834CrossRefPubMed Grünewald S (2009) The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta 1792:827–834CrossRefPubMed
8.
Zurück zum Zitat Erlandson A, Bjursell C, Stibler H, Kristiansson B, Wahlström J, Martinsson T (2001) Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. Hum Genet 108:359–367CrossRefPubMed Erlandson A, Bjursell C, Stibler H, Kristiansson B, Wahlström J, Martinsson T (2001) Scandinavian CDG-Ia patients: genotype/phenotype correlation and geographic origin of founder mutations. Hum Genet 108:359–367CrossRefPubMed
9.
Zurück zum Zitat Pérez-Dueñas B, García-Cazorla A, Pineda M et al (2009) Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestations. Eur J Paediatr Neurol 13:444–451CrossRefPubMed Pérez-Dueñas B, García-Cazorla A, Pineda M et al (2009) Long-term evolution of eight Spanish patients with CDG type Ia: typical and atypical manifestations. Eur J Paediatr Neurol 13:444–451CrossRefPubMed
10.
Zurück zum Zitat de Lonlay P, Seta N, Barrot S et al (2001) A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 38:14–19PubMedCentralCrossRefPubMed de Lonlay P, Seta N, Barrot S et al (2001) A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. J Med Genet 38:14–19PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Barone R, Fiumara A, Jaeken J (2014) Congenital disorders of glycosylation with emphasis on cerebellar involvement. Semin Neurol 34:357–366CrossRefPubMed Barone R, Fiumara A, Jaeken J (2014) Congenital disorders of glycosylation with emphasis on cerebellar involvement. Semin Neurol 34:357–366CrossRefPubMed
12.
Zurück zum Zitat Sturiale L, Barone R, Palmigiano A et al (2008) Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS. Proteomics 8:3822–3832CrossRefPubMed Sturiale L, Barone R, Palmigiano A et al (2008) Multiplexed glycoproteomic analysis of glycosylation disorders by sequential yolk immunoglobulins immunoseparation and MALDI-TOF MS. Proteomics 8:3822–3832CrossRefPubMed
13.
Zurück zum Zitat Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J (1998) Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet 62:542–550PubMedCentralCrossRefPubMed Matthijs G, Schollen E, Van Schaftingen E, Cassiman JJ, Jaeken J (1998) Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A. Am J Hum Genet 62:542–550PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Pavone L, Fiumara A, Barone R et al (1996) Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I. J Neurol 243:700–705CrossRefPubMed Pavone L, Fiumara A, Barone R et al (1996) Olivopontocerebellar atrophy leading to recognition of carbohydrate-deficient glycoprotein syndrome type I. J Neurol 243:700–705CrossRefPubMed
15.
Zurück zum Zitat Veneselli E, Biancheri R, Di Rocco M, Tortorelli S (1998) Neurophysiological findings in a case of carbohydrate-deficient glycoprotein (CDG) syndrome type I with phosphomannomutase deficiency. Eur J Paediatr Neurol 2:239–244CrossRefPubMed Veneselli E, Biancheri R, Di Rocco M, Tortorelli S (1998) Neurophysiological findings in a case of carbohydrate-deficient glycoprotein (CDG) syndrome type I with phosphomannomutase deficiency. Eur J Paediatr Neurol 2:239–244CrossRefPubMed
16.
Zurück zum Zitat Bortot B, Cosentini D, Faletra F, Biffi S, De Martino E, Carrozzi M, Severini GM (2013) PMM2-CDG: phenotype and genotype in four affected family members. Gene 531:506–509CrossRefPubMed Bortot B, Cosentini D, Faletra F, Biffi S, De Martino E, Carrozzi M, Severini GM (2013) PMM2-CDG: phenotype and genotype in four affected family members. Gene 531:506–509CrossRefPubMed
17.
Zurück zum Zitat Barone R, Sturiale L, Fiumara A, Uziel G, Garozzo D, Jaeken J (2007) Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype). J Inherit Metab Dis 30:107CrossRefPubMed Barone R, Sturiale L, Fiumara A, Uziel G, Garozzo D, Jaeken J (2007) Borderline mental development in a congenital disorder of glycosylation (CDG) type Ia patient with multisystemic involvement (intermediate phenotype). J Inherit Metab Dis 30:107CrossRefPubMed
18.
Zurück zum Zitat Di Rocco M, Barone R, Adami A et al (2000) Carbohydrate-deficient glycoprotein syndromes: the Italian experience. J Inherit Metab Dis 23:391–395CrossRefPubMed Di Rocco M, Barone R, Adami A et al (2000) Carbohydrate-deficient glycoprotein syndromes: the Italian experience. J Inherit Metab Dis 23:391–395CrossRefPubMed
19.
Zurück zum Zitat Haeuptle MA, Hennet T (2009) Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum Mutat 30:1628–1641CrossRefPubMed Haeuptle MA, Hennet T (2009) Congenital disorders of glycosylation: an update on defects affecting the biosynthesis of dolichol-linked oligosaccharides. Hum Mutat 30:1628–1641CrossRefPubMed
20.
Zurück zum Zitat Kjaergaard S, Schwartz M, Skovby F (2001) Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch Dis Child 85:236–239PubMedCentralCrossRefPubMed Kjaergaard S, Schwartz M, Skovby F (2001) Congenital disorder of glycosylation type Ia (CDG-Ia): phenotypic spectrum of the R141H/F119L genotype. Arch Dis Child 85:236–239PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Linssen M, Mohamed M, Wevers RA, Lefeber DJ, Morava E (2013) Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab 109:107–111CrossRefPubMed Linssen M, Mohamed M, Wevers RA, Lefeber DJ, Morava E (2013) Thrombotic complications in patients with PMM2-CDG. Mol Genet Metab 109:107–111CrossRefPubMed
22.
Zurück zum Zitat Horslen SP, Clayton PT, Harding BN, Hall NA, Keir G, Winchester B (1991) Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child 66:1027–1032PubMedCentralCrossRefPubMed Horslen SP, Clayton PT, Harding BN, Hall NA, Keir G, Winchester B (1991) Olivopontocerebellar atrophy of neonatal onset and disialotransferrin developmental deficiency syndrome. Arch Dis Child 66:1027–1032PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Drouin-Garraud V, Belgrand M, Grünewald S et al (2001) Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling. Am J Med Genet 101:46–49CrossRefPubMed Drouin-Garraud V, Belgrand M, Grünewald S et al (2001) Neurological presentation of a congenital disorder of glycosylation CDG-Ia: implications for diagnosis and genetic counseling. Am J Med Genet 101:46–49CrossRefPubMed
24.
Zurück zum Zitat Aronica E, van Kempen AA, van der Heide M et al (2005) Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol 109:433–442CrossRefPubMed Aronica E, van Kempen AA, van der Heide M et al (2005) Congenital disorder of glycosylation type Ia: a clinicopathological report of a newborn infant with cerebellar pathology. Acta Neuropathol 109:433–442CrossRefPubMed
25.
Zurück zum Zitat Vedolin L, Gonzalez G, Souza CF, Lourenço C, Barkovich AJ (2013) Inherited cerebellar ataxia in childhood: a pattern-recognition approach using brain MRI. Am J Neuroradiol 34:925–934CrossRefPubMed Vedolin L, Gonzalez G, Souza CF, Lourenço C, Barkovich AJ (2013) Inherited cerebellar ataxia in childhood: a pattern-recognition approach using brain MRI. Am J Neuroradiol 34:925–934CrossRefPubMed
26.
Zurück zum Zitat Sun L, Zhao Y, Zhou K, Freeze HH, Zhang YW, Xu H (2013) Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation. Mol Brain 6:52–60PubMedCentralCrossRefPubMed Sun L, Zhao Y, Zhou K, Freeze HH, Zhang YW, Xu H (2013) Insufficient ER-stress response causes selective mouse cerebellar granule cell degeneration resembling that seen in congenital disorders of glycosylation. Mol Brain 6:52–60PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Lo WY, Lagrange AH, Hernandez CC, Harrison R, Dell A, Haslam SM et al (2010) Glycosylation of b2 subunits regulates GABAA receptor biogenesis and channel gating. J Biol Chem 285:31348–31361PubMedCentralCrossRefPubMed Lo WY, Lagrange AH, Hernandez CC, Harrison R, Dell A, Haslam SM et al (2010) Glycosylation of b2 subunits regulates GABAA receptor biogenesis and channel gating. J Biol Chem 285:31348–31361PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F et al (2000) Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 16:386–394CrossRefPubMed Matthijs G, Schollen E, Bjursell C, Erlandson A, Freeze H, Imtiaz F et al (2000) Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Hum Mutat 16:386–394CrossRefPubMed
29.
Zurück zum Zitat Bjursell C, Erlandson A, Nordling M, Nilsson S, Wahlström J, Stibler H et al (2000) PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Hum Mutat 16:395–400CrossRefPubMed Bjursell C, Erlandson A, Nordling M, Nilsson S, Wahlström J, Stibler H et al (2000) PMM2 mutation spectrum, including 10 novel mutations, in a large CDG type 1A family material with a focus on Scandinavian families. Hum Mutat 16:395–400CrossRefPubMed
30.
Zurück zum Zitat Pérez B, Briones P, Quelhas D, Artuch R, Vega AI, Quintana E, Gort L et al (2011) The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. J Inherit Metab Dis Rep 1:117–123 Pérez B, Briones P, Quelhas D, Artuch R, Vega AI, Quintana E, Gort L et al (2011) The molecular landscape of phosphomannose mutase deficiency in iberian peninsula: identification of 15 population-specific mutations. J Inherit Metab Dis Rep 1:117–123
31.
Zurück zum Zitat Westphal V, Peterson S, Patterson M et al (2001) Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia. Genet Med 3:393–398CrossRefPubMed Westphal V, Peterson S, Patterson M et al (2001) Functional significance of PMM2 mutations in mildly affected patients with congenital disorders of glycosylation Ia. Genet Med 3:393–398CrossRefPubMed
32.
Zurück zum Zitat Coman D, McGill J, MacDonald R et al (2007) Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype. J Clin Neurosci 14:668–672CrossRefPubMed Coman D, McGill J, MacDonald R et al (2007) Congenital disorder of glycosylation type 1a: three siblings with a mild neurological phenotype. J Clin Neurosci 14:668–672CrossRefPubMed
33.
Zurück zum Zitat Vega AI, Pérez-Cerdá C, Abia D et al (2011) Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis 34:929–939CrossRefPubMed Vega AI, Pérez-Cerdá C, Abia D et al (2011) Expression analysis revealing destabilizing mutations in phosphomannomutase 2 deficiency (PMM2-CDG): expression analysis of PMM2-CDG mutations. J Inherit Metab Dis 34:929–939CrossRefPubMed
34.
Zurück zum Zitat Vuillaumier-Barrot S, Hetet G, Barnier A et al (2000) Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. J Med Genet 37:579–580CrossRefPubMed Vuillaumier-Barrot S, Hetet G, Barnier A et al (2000) Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. J Med Genet 37:579–580CrossRefPubMed
35.
Zurück zum Zitat Mills K, Mills P, Jackson M et al (2006) Diagnosis of congenital disorders of glycosylation type-I using protein chip technology. Proteomics 6:2295–2304CrossRefPubMed Mills K, Mills P, Jackson M et al (2006) Diagnosis of congenital disorders of glycosylation type-I using protein chip technology. Proteomics 6:2295–2304CrossRefPubMed
36.
Zurück zum Zitat Barone R, Sturiale V, Sofia A et al (2008) Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia. Am J Med Genet A 146A:2103–2108CrossRefPubMed Barone R, Sturiale V, Sofia A et al (2008) Clinical phenotype correlates to glycoprotein phenotype in a sib pair with CDG-Ia. Am J Med Genet A 146A:2103–2108CrossRefPubMed
37.
Zurück zum Zitat Hülsmeier AJ, Paesold-Burda P, Hennet T (2007) N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics 6:2132–2138CrossRefPubMed Hülsmeier AJ, Paesold-Burda P, Hennet T (2007) N-glycosylation site occupancy in serum glycoproteins using multiple reaction monitoring liquid chromatography-mass spectrometry. Mol Cell Proteomics 6:2132–2138CrossRefPubMed
Metadaten
Titel
A nationwide survey of PMM2-CDG in Italy: high frequency of a mild neurological variant associated with the L32R mutation
verfasst von
Rita Barone
M. Carrozzi
R. Parini
R. Battini
D. Martinelli
M. Elia
M. Spada
F. Lilliu
G. Ciana
A. Burlina
V. Leuzzi
M. Leoni
L. Sturiale
G. Matthijs
J. Jaeken
M. Di Rocco
D. Garozzo
A. Fiumara
Publikationsdatum
01.01.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 1/2015
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-014-7549-7

Weitere Artikel der Ausgabe 1/2015

Journal of Neurology 1/2015 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.